Oxford Biomedica (LON:OXB) Releases Earnings Results

Oxford Biomedica (LON:OXB) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%.

Oxford Biomedica Stock Down 2.5%

Shares of LON OXB opened at GBX 480.50 on Wednesday. The company’s 50 day moving average price is GBX 515.68 and its 200-day moving average price is GBX 577.12. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a 52-week low of GBX 420 and a 52-week high of GBX 952. The company has a market capitalization of £581.64 million, a P/E ratio of -17.85 and a beta of 1.09.

More Oxford Biomedica News

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Revenue growth and new business wins: Oxford Biomedica reported first-half revenue of £80.2 million, up 9%, while securing 17 new clients—a record for the company. The wins suggest continued demand for its cell and gene therapy development and manufacturing services. Oxford Biomedica delivers solid H1 growth, record commercial wins
• Positive Sentiment: Full-year guidance maintained: Management reiterated its sales outlook for 2026, reducing the risk of a near-term guidance downgrade and indicating confidence in the company’s growth pipeline. Oxford Biomedica H1 Revenue Reaches £80.2 Million as FY2026 Guidance Maintained
• Positive Sentiment: Operational modernization: Oxford Biomedica is advancing a global quality transformation using Veeva Quality Cloud, which could improve consistency, compliance and efficiency across its operations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: Analyst interest remains constructive: A pre-results valuation analysis identified potential upside, although this is an external estimate rather than company guidance and does not remove execution risk. Earnings To Watch: Oxford BioMedica PLC Q2 2026
• Negative Sentiment: Losses remain the key concern: Oxford Biomedica reported quarterly EPS of negative GBX30.39, with a 17.85% net loss margin and a negative 48.56% return on equity. The half-year loss widened, overshadowing revenue growth and client additions. Oxford Biomedica reiterates sales outlook but half-year loss widens

Analyst Ratings Changes

OXB has been the subject of several recent research reports. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 595 price target on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.